Navigation Links
Off-label and Untested Use of Drug-coated Stents Appears Widespread

The off-label and untested use of drug-coated stents in the treatment of coronary artery blockage is common in U.S. practice, and ischemic complication rates are higher among patients receiving drug-coated stents for off-label indications, according to two studies in the May 9 issue of JAMA.

Stents are tiny mesh tubes used to prop open an artery after balloon angioplasty is used to open an obstructed coronary artery. The newer drug-eluting stents are normal metal stents coated with a drug that is known to interfere with the process of restenosis (re-obstruction).

Data on the use of drug-eluting stents outside of approved indications in real-world settings are limited, according to background information in the articles.

Nirat Beohar, M.D., of Northwestern University Feinberg School of Medicine, Chicago, and colleagues analyzed data from the D.E.S.cover Registry - a prospective, multicenter, observational study conducted at 140 U.S. academic and community hospitals, and consisting of 7,752 patients who underwent percutaneous coronary intervention (PCI, balloon angioplasty) between January and June 2005. The study objective was to determine the frequency, safety, and effectiveness of drug-eluting stents for off-label and untested indications. Off-label indications included use of stents for restenosis, bypass graft lesion, and long lesions. Untested indications included left main, ostial, bifurcation, or total occlusion lesions.

The authors observed that approximately half of all use of drug-eluting stents occurs in off-label or untested settings. "Of 5,541 patients receiving drug-eluting stents, 2,588 (47 percent) received stents for off-label or untested indications," they write.

"Compared with patients receiving drug-eluting stents for standard indications, those receiving such stents for off-label and untested indications tended to present with more severe clinical profiles, which would have excluded these p atients from the pivotal randomized trials that led to FDA approval of drug-eluting stents," they continue.

The authors report a significant difference in clinical outcome for patients in the off-label group was clearly evident by the 30-day follow-up. "Both observed and adjusted analyses indicated a greater than two-fold higher risk of death, MI [myocardial infarction, heart attack], or stent thrombosis [formation of a blood clot]," they write.

"Compared with standard use, short-term outcomes appear to be worse with off-label and untested use," the authors conclude. "However, even with off-label or untested use of drug-eluting stents, overall absolute event rates both in hospital and at 12 months following PCI remain relatively low."


'"/>




Related medicine news :

1. No Evidence to Support Many Off-label Uses of Atypical Antipsychotics
2. Babies Are Treated With Untested Drugs
3. Scientists In UK Issue A Caution Over Untested Stem Cell Treatments
4. Drug-coated heart stents under scrutiny, after study
5. Stronger Backing for Drug-Coated Stents
6. Drug-Coated Stents – Proven to be More Effectiv
7. The Efficacy Of Newer Stents Questioned
8. Analyzing The Side Effects Of Sirolimus Stents
9. Stents That Release Medication To Check Artery Narrowing
10. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
11. Drug-Eluting Stents Ensure Patency Of The Saphenous Vein Grafts
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/26/2017)... ... 2017 , ... Two innovative companies are bringing to market ... is scientifically proven as well: ABAlife™. Euromed SA, a leading manufacturer of therapeutic ... with BioTherapeutics Inc. for patented technology for absiscic acid (ABA). , The ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... Manufacturers, **An FDAnews Management Report**, http://www.fdanews.com/products/54648-principles-of-equipment-qualification      , The ... must prove that their equipment, operations and processes all work the way ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... ... orthopedic surgeon and the Chair of the Leg, Ankle, and Foot Section of ... currently the only fellowship trained orthopedic surgeon at Hackensack UMC performing total ankle ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... Premier Inc. Effective October 1, 2017, the new agreement allows Premier members, at ... for patient scales. , “DETECTO is pleased to renew our agreement with Premier ...
(Date:9/26/2017)... ... 26, 2017 , ... “Good Morning Sunshine!: Finding Strength and Comfort in God”: ... Sunshine!: Finding Strength and Comfort in God” is the creation of published author, Terri ... University, who has worked at a local mental health center for over twenty years, ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , Sept. ... Penn. , and OptiMed Specialty Pharmacy of ... partnership to offer a strategic hub service that expedites ... highly sought-after personal spirometer, Spiro PD 2.0, and wellness ... A spirometer is a medical device used to measure ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/9/2017)... WASHINGTON , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, ... to Washington, D.C. offering free MRI brain scans to the public.Where:  ... – will be parked at 501 K Street NW, Washington, D.C.What:BTF brings ...
Breaking Medicine Technology: